All In Biotech

Drug Trial Radar · NCT07496372

A Pivotal Clinical Trial of Human Induced Pluripotent Stem Cell-derived Cardiomyocytes Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

A Pivotal Multicenter, Randomized, Controlled Trial to Evaluate the Efficacy and Safety of Intramyocardial Injection of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) for the Treatment of Advanced Heart Failure(NYHA III-IV)

Last checked: Nov 19, 2026Latest source record: May 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Title says "pivotal". This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

80

Planned (sponsor's estimate)

Start

Apr 30, 2026

Primary completion

Jun 30, 2027

Study completion Aug 31, 2027

Sponsor

Lead sponsor
HELP Therapeutics Co., Ltd.Industry
Sponsor type
Industry
First posted
Mar 27, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this clinical study is to evaluate the efficacy and safety of intramyocardial injection of human induced pluripotent stem cell-derived cardiomyocyte injection (HiCM-188) in patients with advanced heart failure (NYHA Class III-IV)

Conditions

  • Heart Failure

Interventions

  • HiCM-188 therapyBiological

    Intramyocardial Injection of Human Induced Pluripotent Stem Cell-Derived Cardiomyocyte Injection (HiCM-188) during coronary artery bypass grafting surgery

  • CABG surgeryProcedure

    Conventional coronary artery bypass grafting (CABG) surgery

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. 6-minute walk distance (6MWD)Time frame: 12 months after surgery

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • TEDA International Cardiovascular Hospital

    Tianjin, Tianjin Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.